The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review

Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus

(2013) Catherine Sheffield et al.   Endocrine Practice

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*

(2011) K. Y. Thong et al.   DIABETES OBESITY & METABOLISM

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

(2010) E. S. Horton et al.   DIABETES CARE

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations

(2010) Ajay Varanasi et al.   Endocrine Practice

Exenatide therapy in insulin-treated type 2 diabetes and obesity

(2010) U. A. Nayak et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis

(2010) Manjiri Pawaskar et al.   JOURNAL OF MEDICAL ECONOMICS

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

(2009) Nancy M. Yoon et al.   CLINICAL THERAPEUTICS

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

(2009) Richard Bergenstal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization

(2009) Catherine E. Cooke et al.   CURRENT MEDICAL RESEARCH AND OPINION

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

(2009) Rosalind Fabunmi et al.   CURRENT MEDICAL RESEARCH AND OPINION

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

(2009) C. McAdam-Marx et al.   DIABETES OBESITY & METABOLISM

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

(2009) D. I. Brixner et al.   DIABETES OBESITY & METABOLISM

Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting

(2009) Rajat Bhushan et al.   Diabetes Technology & Therapeutics

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

(2009) Takashi KADOWAKI et al.   ENDOCRINE JOURNAL

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes

(2008) Adriana Forti et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

(2008) Yan Gao et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET